Post-earnings recap
Reported
Thu, Apr 30, 2026
EPS actual
$0.56
EPS est.
$0.47
EPS surprise
+19.66%
1-day move
+3.46%
DexCom's strong earnings per share performance exceeded expectations, contributing to a positive stock reaction with a 3.46% increase. However, the lack of revenue data and management commentary leaves some uncertainty regarding the company's overall performance and future outlook.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.56 | $0.47 | +19.66% |
| Revenue | N/A | $1.2B | N/A |
No transcript is on record, and the analysis is based on numerical results only.
DexCom, Inc. is a healthcare company that specializes in continuous glucose monitoring systems for people with diabetes. As a leader in health care equipment, its products play a crucial role in managing diabetes, a growing health concern worldwide.
Last quarter
In Q4-2025, DexCom reported an EPS of $0.68, surpassing estimates by 4.62%. However, the stock fell 4.50% the following day, indicating market skepticism despite the earnings beat.
EPS beat streak
5Q
EPS beat rate
63%
Avg EPS surprise
+0.74%
Avg 1-day reaction
-0.02%
Analysts expect DexCom to report earnings of $0.47 per share on $1.2 billion in revenue for Q1-2026. The market is closely watching how the company navigates ongoing competition and product demand.
Bull case
If DexCom can exceed earnings expectations and show strong revenue growth, it may indicate robust demand for its glucose monitoring systems, potentially driving the stock higher.
Bear case
Conversely, if the company misses earnings estimates or provides weak guidance, it could raise concerns about its market position and growth prospects, leading to a decline in stock price.
Key metrics to watch
EPS
0.47Earnings per share is a key indicator of profitability and is closely watched by investors.
Revenue
1.2BRevenue figures help gauge the company's sales performance and market demand for its products.
The print will turn on these.
Q1
Will DexCom's EPS exceed the consensus estimate of $0.47?
A strong earnings report could signal continued demand for its products and boost investor confidence.
Q2
What guidance will management provide regarding revenue growth for the upcoming quarters?
Guidance on future revenue is crucial for understanding the company's growth trajectory and market position.
Est. EPS
$1.89
Est. Rev
$1.5B
Impl. Move
±9.0%
Why consensus could be wrong
The Street may be underestimating DexCom's ability to maintain its market position and revenue growth despite competitive pressures.
Supporting evidence
DexCom has consistently beaten EPS estimates in the past quarters, indicating strong operational performance.
The options market is pricing in a significant move, suggesting that investors expect volatility that may not align with consensus expectations.
Key risk
If management provides strong guidance on revenue growth, it could challenge the current bearish sentiment.
Pre-commit to what would confirm each case.
The market is debating whether DexCom can sustain its growth amid increasing competition and evolving healthcare needs.
Bull confirmed if
An EPS of $0.50 or higher would confirm strong operational performance and positive market sentiment.
Bear confirmed if
An EPS below $0.42 would raise concerns about demand and competitive pressures in the market.
What the market is pricing for the move.
Implied Move
±10.92%
Historical Avg
±1.8%
The options market is pricing in a significant move, indicating that investors expect volatility around the earnings announcement.
Options are pricing ±10.9% while DXCM has averaged ±1.8% over the last 8 prints — setup is pricing rich.
ATM IV
1.9%
30d HV
32.9%
Cross-company pattern from 30 similar setups.
Prior-quarter beat + options rich in Health Care
Fade rate: 7 of 23 (30%)
This setup has occurred 30 times across Health Care in the last 2 years. 16 of 23 (70%) held or extended their move within 5 days — this setup typically holds direction. The average absolute 1-day move is 4.2%, with a raw directional average of +0.6% (modestly positive historical bias).
Smart-money positioning from the most recent 13F filings.
Institutional
106.71%
of float
Insider
0.26%
of float
Holders
1,463
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
38,244,137 sh · $3.2B
10.13%
-1.8%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If DexCom beats expectations, history suggests a potential stock increase of around 1.67%, confirming strong demand and operational efficiency.
In line / cautious
If the results are in line with expectations, the stock may see muted movement as investors await further guidance.
Miss
Should the company miss earnings expectations, history suggests a potential decline of around 0.65%, reflecting investor disappointment.
House and Senate STOCK Act disclosures over the trailing 6 months.
Trades
2
0 buys·2 sells
Members
1
Senate only
Est. Notional
$200,002.00–$500,000.00
disclosed dollar ranges
Most Active Members
2 trades
The lines on the call that would change the story.
Vanguard Capital Management LLC
25,209,752 sh · $2.1B
6.68%
0.8%
Vanguard Portfolio Management LLC
19,656,540 sh · $1.7B
5.21%
2.3%
State Street Corporation
18,380,806 sh · $1.5B
4.87%
2.5%
Invesco Ltd.
15,288,133 sh · $1.3B
4.05%
11.8%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.
Net selling
Recent Transactions
Traded May 7, 2026 · disclosed May 10, 2026
$100,001.00–$250,000.00
Traded Apr 29, 2026 · disclosed May 10, 2026
$100,001.00–$250,000.00
Filed 30–45+ days after the trade. Treat as positional context, not a leading indicator. Amounts are SEC-mandated dollar ranges, not exact values.